NEW YORK (GenomeWeb) – Exosome Diagnostics said today that it has agreed to collaborate with Intezyne to design and validate an exosomal RNA assay for use in Intezyne's Phase 1/2 clinical trials of IT-139, a novel Cancer Resistance Pathway (CRP) inhibitor intended for the treatment of pancreatic, gastric, and other cancers in combination with existing anti-cancer therapies.

The assay will use Exosome Diagnostics' Exolution isolation kit and will be designed to stratify patients and monitor them longitudinally.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.

Feb
21
Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Mar
13
Sponsored by
Horizon Discovery

This webinar will discuss development and validation of an assay for detection of microsatellite instability (MSI) based on a novel set of biomarkers.

Mar
20
Sponsored by
Qiagen

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar
21
Sponsored by
Loop Genomics

This webinar provides a comparison of next-generation sequencing (NGS) approaches for human transcriptome sequencing, including short-read Illumina sequencing and synthetic long-read sequencing technology.